Abstract
Over the past two decades, advances in the understanding of molecular biology have led to the development of an array of new molecular diagnostic tests. As a result, the care of cancer patients is undergoing an impressive revolution from “trial and error” to a “personalized” approach, based on a more detailed understanding of the biology of a patient’s tumor. Hundreds of biomarkers are currently in use to provide diagnostic and prognostic information to clinicians and help determine the optimal treatment regimen for a given tumor and molecular testing is becoming the standard of care for an increasing number of tumors. Basic knowledge of the cell cycle, cell cycle regulators, and the roles of proto-oncogenes, oncogenes, tumor suppressor genes, DNA repair mechanisms, and control of programmed cell death is critical for medical practitioners to keep pace with the rapid molecular revolution and the rationale for targeted therapy. This knowledge is also important to understand the utility and limitations of available tumor biomarkers to ensure appropriate test utilization. It is imperative that medical practitioners especially pathologists and oncologists keep abreast of these rapid developments in order to provide contemporary care to cancer patients. This chapter provides an overview of basic molecular tumor pathology and targeted therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jorde LBCJ, Bamshad MJ, editors. Medical genetics. 4th ed. Philadelphia, PA: Mosby/Elsevier; 2010.
Hoeijmakers JH. Genome maintenance mechanisms are critical for preventing cancer as well as other aging-associated diseases. Mech Ageing Dev. 2007;128(7-8):460–2.
Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–85.
Luijsterburg MS, van Attikum H. Chromatin and the DNA damage response: the cancer connection. Mol Oncol. 2011;5(4):349–67.
Morrison AJ, Shen X. DNA repair in the context of chromatin. Cell Cycle. 2005;4(4):568–71.
Reddy KL, Feinberg AP. Higher order chromatin organization in cancer. Semin Cancer Biol. 2013;23(2):109–15.
Gondor A. Nuclear architecture and chromatin structure on the path to cancer. Semin Cancer Biol. 2013;23(2):63–4.
Page SL, Hawley RS. Chromosome choreography: the meiotic ballet. Science. 2003;301(5634):785–9.
Nebert DW. Transcription factors and cancer: an overview. Toxicology. 2002;181–182:131–41.
De Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis. 2004;19(3):169–85.
Sander M, Cadet J, Casciano DA, Galloway SM, Marnett LJ, Novak RF, et al. Proceedings of a workshop on DNA adducts: biological significance and applications to risk assessment Washington, DC, April 13–14, 2004. Toxicol Appl Pharmacol. 2005;208(1):1–20.
Nagai H, Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys. 2010;502(1):1–7.
Moyer VD, Cistulli CA, Vaslet CA, Kane AB. Oxygen radicals and asbestos carcinogenesis. Environ Health Perspect. 1994;102 Suppl 10:131–6.
Tirnitz-Parker JE, Glanfield A, Olynyk JK, Ramm GA. Iron and hepatic carcinogenesis. Crit Rev Oncog. 2013;18(5):391–407.
Mariani F, Sena P, Roncucci L. Inflammatory pathways in the early steps of colorectal cancer development. World J Gastroenterol. 2014;20(29):9716–31.
Sekine Y, Hata A, Koh E, Hiroshima K. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment. Gen Thorac Cardiovasc Surg. 2014;62(7):415–21.
Mullin JM. Epithelial barriers, compartmentation, and cancer. Sci STKE. 2004;2004(216), e2.
Bishop WP, Wen JT. Regulation of Caco-2 cell proliferation by basolateral membrane epidermal growth factor receptors. Am J Physiol. 1994;267(5 Pt 1):G892–900.
Watson CJ, Rowland M, Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell physiol. 2001;281(2):C388–97.
Verkman AS, Anderson MO, Papadopoulos MC. Aquaporins: important but elusive drug targets. Nat Rev Drug Discov. 2014;13(4):259–77.
Verkman AS, Hara-Chikuma M, Papadopoulos MC. Aquaporins – new players in cancer biology. J Mol Med. 2008;86(5):523–9.
Hara-Chikuma M, Verkman AS. Prevention of skin tumorigenesis and impairment of epidermal cell proliferation by targeted aquaporin-3 gene disruption. Mol Cell Biol. 2008;28(1):326–32.
Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. J Exp Clin Cancer Res. 2014;33:38.
Zhang Z, Chen Z, Song Y, Zhang P, Hu J, Bai C. Expression of aquaporin 5 increases proliferation and metastasis potential of lung cancer. J Pathol. 2010;221(2):210–20.
Jung HJ, Park JY, Jeon HS, Kwon TH. Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One. 2011;6(12), e28492.
Di Giusto G, Flamenco P, Rivarola V, Fernandez J, Melamud L, Ford P, et al. Aquaporin 2-increased renal cell proliferation is associated with cell volume regulation. J Cell Biochem. 2012;113(12):3721–9.
Huang YH, Zhou XY, Wang HM, Xu H, Chen J, Lv NH. Aquaporin 5 promotes the proliferation and migration of human gastric carcinoma cells. Tumour Biol. 2013;34(3):1743–51.
Goldschneider D, Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene. 2010;29(13):1865–82.
Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol. 2006;8(2):77–82.
Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008;99(2):214–20.
Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology. 2013;154(5):1672–9.
Kampen KR. Membrane proteins: the key players of a cancer cell. J Membr Biol. 2011;242(2):69–74.
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2(3):135–64.
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 2011;3(3):192–222.
Bertelsen V, Stang E. The mysterious ways of ErbB2/HER2 trafficking. Membranes (Basel). 2014;4(3):424–46.
Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.
Carpenter G, Liao HJ. Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res. 2009;315(9):1556–66.
Johnson HM, Subramaniam PS, Olsnes S, Jans DA. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. BioEssays. 2004;26(9):993–1004.
Bryant DM, Stow JL. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic. 2005;6(10):947–54.
Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009;15(21):6484–9.
Olsnes S, Klingenberg O, Wiedlocha A. Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev. 2003;83(1):163–82.
Planque N. Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers. Cell Commun Signal. 2006;4:7.
Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer. 2006;94(2):184–8.
Polivka Jr J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164–75.
Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 2014;40(6):750–9.
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets. 2010;10(5):433–61.
Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19(2):238–45.
Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol. 2001;13(6):738–47.
Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306.
Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med. 2006;7(3):165–72.
Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res. 2008;14(13):4032–7.
Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23.
Poehlmann A, Roessner A. Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract. 2010;206(9):591–601.
Aarts M, Linardopoulos S, Turner NC. Tumour selective targeting of cell cycle kinases for cancer treatment. Curr Opin Pharmacol. 2013;13(4):529–35.
Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012;22(4):211–9.
Gallorini M, Cataldi A, di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs. 2012;26(6):377–91.
Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320–8.
Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother. 2014;15(7):991–1004.
Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene. 2011;30(25):2799–809.
Kaestner P, Bastians H. Mitotic drug targets. J Cell Biochem. 2010;111(2):258–65.
Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol. 2012;4(12).
Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–11.
Bottos A, Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci. 2013;70(21):4131–40.
Guo XE, Ngo B, Modrek AS, Lee WH. Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets. 2014;15(1):2–16.
Stella GM, Luisetti M, Pozzi E, Comoglio PM. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med. 2013;1(3):251–61.
Vicente-Duenas C, Romero-Camarero I, Cobaleda C, Sanchez-Garcia I. Function of oncogenes in cancer development: a changing paradigm. EMBO J. 2013;32(11):1502–13.
Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15(1):80–9.
Avalos Y et al. Tumor suppression and promotion by autophagy. Biomed Res Int. 2014;2014:603980.
Merino D, Malkin D. p53 and hereditary cancer. Subcell Biochem. 2014;85:1–16.
Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319.
Fatemian T, Chowdhury EH. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance. Curr Cancer Drug Targets. 2014;14(7):599–609.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.
Wang S, Bai L, Lu J, Liu L, Yang CY, Sun H. Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 2012;17(3-4):217–28.
de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 2012;34(3):200–11.
Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620–33.
Rami MS. Apoptosis and pathological process. Lik Sprava. 2007;8:68–70.
Krammer PH. CD95’s deadly mission in the immune system. Nature. 2000;407(6805):789–95.
Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80(2):131–7.
Arlt A, Muerkoster SS, Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2013;332(2):346–58.
Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med. 2011;11(8):633–49.
Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem. 2014;57(9):3666–77.
Sancar A. DNA repair in humans. Annu Rev Genet. 1995;29:69–105.
Gospodinov A, Herceg Z. Chromatin structure in double strand break repair. DNA Repair. 2013;12(10):800–10.
Pierce AJ, Stark JM, Araujo FD, Moynahan ME, Berwick M, Jasin M. Double-strand breaks and tumorigenesis. Trends Cell Biol. 2001;11(11):S52–9.
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179–204.
Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J. hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. Curr Biol. 1996;6(9):1181–4.
Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011;135(10):1269–77.
Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2014;16(1):101–16.
Longley MJ, Pierce AJ, Modrich P. DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem. 1997;272(16):10917–21.
Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 2003;193(1-2):3–34.
Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 2000;19(13):3398–407.
Sonoda E, Takata M, Yamashita YM, Morrison C, Takeda S. Homologous DNA recombination in vertebrate cells. Proc Natl Acad Sci U S A. 2001;98(15):8388–94.
Venkitaraman AR. Tracing the network connecting brca and fanconi anaemia proteins. Nat Rev Cancer. 2004;4(4):266–76.
Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res. 2005;65(24):11384–91.
Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408(6811):429–32.
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.
Ms M. Chromosome instability syndromes: lessons for carcinogenesis. Curr Top Microbiol Immunol. 1997;221:71–148.
Christ N, Moynahan M, Jasin M. BRCA2: safeguarding the genome through homologous recombination. In: Aguilera A, Rothstein R, editors. Molecular genetics of recombination, Topics in Current Genetics, vol. 17. Heidelberg: Springer; 2007. p. 363–80.
Pellegrini L, Venkitaraman A. Emerging functions of BRCA2 in DNA recombination. Trends Biochem Sci. 2004;29(6):310–6.
Kennedy RD, D’Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19(24):2925–40.
Minoo P. Toward a molecular classification of colorectal cancer: the role of MGMT. Front Oncol. 2013;3:266.
Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med. 2008;359(7):722–34.
Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–3.
Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. Nat Rev Genet. 2002;3(10):769–78.
Mitelman F, Mertens F, Johansson B. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer. 2005;43(4):350–66.
Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34(4):369–76.
Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367(7):647–57.
Lemon B, Tjian R. Orchestrated response: a symphony of transcription factors for gene control. Genes Dev. 2000;14(20):2551–69.
Nair SS, Kumar R. Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol. 2012;6(6):611–9.
Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409–20.
Gregory RI, Shiekhattar R. Chromatin modifiers and carcinogenesis. Trends Cell Biol. 2004;14(12):695–702.
Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28.
Bignold LP. Pathogenetic mechanisms of nuclear pleomorphism of tumour cells based on the mutator phenotype theory of carcinogenesis. Histol Histopathol. 2003;18(2):657–64.
Forger 3rd JM, Choie DD, Friedberg EC. Non-histone chromosomal proteins of chemically transformed neoplastic cells in tissue culture. Cancer Res. 1976;36(1):258–62.
Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–3.
Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396–8.
Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143–53.
Richardson B. Impact of aging on DNA methylation. Ageing Res Rev. 2003;2(3):245–61.
Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27.
Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007;56(11):1564–71.
Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89–92.
Liu WR, Shi YH, Peng YF, Fan J. Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J (Engl). 2012;125(13):2349–60.
Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, et al. DNA hypermethylation as a chemotherapy target. Cell Signal. 2011;23(7):1082–93.
Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 2014;9(9):1932–56.
Huang T, Alvarez A, Hu B, Cheng SY. Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer. 2013;32(11):582–93.
Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–55.
Li L, Liu Y. Diverse small non-coding RNAs in RNA interference pathways. Methods Mol Biol. 2011;764:169–82.
Hagan JP, Croce CM. MicroRNAs in carcinogenesis. Cytogenet Genome Res. 2007;118(2-4):252–9.
Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer. 2007;43(10):1529–44.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–11.
Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7(16):2485–92.
Rovira C, Guida MC, Cayota A. MicroRNAs and other small silencing RNAs in cancer. IUBMB Life. 2010;62(12):859–68.
Scholzova E, Malik R, Sevcik J, Kleibl Z. RNA regulation and cancer development. Cancer Lett. 2007;246(1-2):12–23.
Campbell TN, Choy FY. RNA interference: past, present and future. Curr Issues Mol Biol. 2005;7(1):1–6.
Bora RS, Gupta D, Mukkur TK, Saini KS. RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Rep. 2012;6(1):9–15.
Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
Maruyama R, Suzuki H. Long noncoding RNA involvement in cancer. BMB Rep. 2012;45(11):604–11.
He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, et al. Long noncoding RNAs: novel insights into hepatocellular carcinoma. Cancer Lett. 2014;344(1):20–7.
Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108(12):2419–25.
Sanchez Y, Huarte M. Long non-coding RNAs: challenges for diagnosis and therapies. Nucl Acid Ther. 2013;23(1):15–20.
Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66.
Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368(9):842–51.
Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia. 2014;28(1):34–43.
Murugaesu N, Chew SK, Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol. 2013;182(6):1962–71.
Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Models Mech. 2014;7(8):941–51.
Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer. 1980;46(6):1307–18.
Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251–75.
Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149–53.
Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998;95(10):5579–83.
Liu CC, Shen Z, Kung HF, Lin MC. Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol. 2006;12(43):6941–8.
Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190–200.
Bruno A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, et al. Orchestration of angiogenesis by immune cells. Front Oncol. 2014;4:131.
Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27(20):2192–206.
Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.
Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol. 2014;35(9):8483–523.
Engers R, Gabbert HE. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol. 2000;126(12):682–92.
Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83(2):337–76.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.
Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80(8 Suppl):1529–37.
Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49–54.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Surve, D., Idowu, M.O. (2015). Molecular Biology Basics in the “Omics” Era: Cancer Pathology. In: Idowu, M., Dumur, C., Garrett, C. (eds) Molecular Oncology Testing for Solid Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-16304-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-16304-8_2
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16303-1
Online ISBN: 978-3-319-16304-8
eBook Packages: MedicineMedicine (R0)